Exane Asset Management’s Pfizer PFE Stock Holding History

Exane Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,821	Closed	-$384K	–	44
2025 Q3	$384K	Buy	+12,821	New	+$316K	0.13%	21
2019 Q3	–	Sell	-84,173	Closed	-$3.46M	–	42
2019 Q2	$3.46M	Buy	84,173 +4,995	+6%	+$198K	1.54%	21
2019 Q1	$3.19M	Buy	+79,178	New	+$3.17M	1.55%	21
2018 Q4	–	Sell	-12,648	Closed	-$529K	–	155
2018 Q3	$529K	Buy	+12,648	New	+$487K	0.17%	51

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Exane Asset Management's PFE Position: Q4 2025 in Review

Exane Asset Management sold out of Pfizer (PFE) in Q4 2025, closing a stake of 12,821 shares — an estimated $384K sold.

Exane Asset Management first reported a position in PFE in Q3 2018 and held it in 4 quarters. The position peaked at $3.46M in Q2 2019. 2,914 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

Exane Asset Management reported no remaining Pfizer position as of Q4 2025 after selling out during the quarter.
Exane Asset Management sold 12,821 Pfizer shares in Q4 2025, an estimated $384K.
Exane Asset Management first reported a position in Pfizer in Q3 2018 and held it in 4 quarters.
Exane Asset Management's Pfizer position peaked at $3.46M in Q2 2019.
2,914 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on Exane Asset Management's 13F filing for Q4 2025, filed 27 Jan 2026.